Sixth U.S. Patent Issued to Dyadic International
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, announced that it has been issued U.S. Patent No. 7,794,962 by the United States Patent and Trademark Office (USPTO).
The invention embodied by this patent provides a method for the expression and subsequent screening of DNA libraries in filamentous fungal hosts which may help speed up the discovery of novel genes and development of their corresponding enzymes and proteins. The newly issued patent is accessible on the USPTO’s website or on Dyadic’s website.
This patent is the sixth U.S. patent issued to Dyadic adding to its portfolio of 60 international patents and more than 40 pending patent applications worldwide which cover various features of Dyadic’s proprietary technologies.
Dyadic’s President and Chief Executive Officer, Mark Emalfarb, stated, “As with our entire patent portfolio, we believe that this patent will help us further enhance our intellectual property protection of Dyadic’s cutting edge technologies, provide additional potential licensing opportunities and strengthen our competitive market position.”
The invention embodied by this patent provides a method for the expression and subsequent screening of DNA libraries in filamentous fungal hosts which may help speed up the discovery of novel genes and development of their corresponding enzymes and proteins. The newly issued patent is accessible on the USPTO’s website or on Dyadic’s website.
This patent is the sixth U.S. patent issued to Dyadic adding to its portfolio of 60 international patents and more than 40 pending patent applications worldwide which cover various features of Dyadic’s proprietary technologies.
Dyadic’s President and Chief Executive Officer, Mark Emalfarb, stated, “As with our entire patent portfolio, we believe that this patent will help us further enhance our intellectual property protection of Dyadic’s cutting edge technologies, provide additional potential licensing opportunities and strengthen our competitive market position.”
